Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 228-231

  Stieber, Petra ^a   Nagel, Dorothea ^a   Blankenburg, Irene ^a   Heinemann, Volker ^a   Untch, Michael ^b   Bauerfeind, Ingo ^c   Di Gioia, Dorit ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Helios Klinikum   (Germany)

^c Klinikum Landshut   (Germany)

Author keywords

Breast cancer; CA 15 3; CEA; Early detection; Increase; Kinetics; Metastatic disease; Recurrent disease; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; MUCIN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST METASTASIS; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; KINETICS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BLOOD; BREAST NEOPLASMS; FEMALE; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KINETICS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84937242999     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.06.022     Document Type: Article

References (32)

1. Duffy M.J. Serum tumor markers in breast cancer: are they of clinical value?. Clin. Chem. 2006, 52:345-351.
2. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol. 2005, 26:281-293.
3. Cheung K.L., Graves C.R., Robertson J.F. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 2000, 26:91-102.
4. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
5. Molina R., Zanon G., Filella X., et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res. Treat. 1995, 36:41-48.
6. Tomlinson I.P., Whyman A., Barrett J.A., Kremer J.K. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur. J. Cancer 1995, 31A:899-902.
7. Nicolini A., Colombini C., Luciani L., Carpi A., Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br. J. Cancer 1991, 64:154-158.
8. Soletormos G., Nielsen D., Schioler V., Mouridsen H., Dombernowsky P. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur. J. Cancer 2004, 40:481-486.
9. Gion M., Barioli P., Mione R., et al. Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). Ann. Oncol. 1995, 6(Suppl. 2):31-35.
10. Robertson J.F., Jaeger W., Syzmendera J.J., et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur. J. Cancer 1999, 35:47-53.
11. Nicolini A., Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol. 2000, 21:235-248.
12. Untch M., Sauer H., Stieber P. Tumor markers in breast cancer. J. Lab. Med. 2001, 25:343-352.
13. Ebeling F.C., Schmitt U.M., Untch M., et al. Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer-univariate and multivariate analysis. Anticancer Res. 1999, 19:2545-2550.
14. Ebeling F.G., Stieber P., Untch M., et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br. J. Cancer 2002, 86:1217-1222.
15. Colomer R., Ruibal A., Genolla J., et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res. Treat. 1989, 13:123-133.
16. Guadagni F., Ferroni P., Carlini S., et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin. Cancer Res. 2001, 7:2357-2362.
17. Jager W., Kramer S., Palapelas V., Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand. J. Clin. Lab. Invest. Suppl. 1995, 221:87-92.
18. Kallioniemi O.P., Oksa H., Aaran R.K., Hietanen T., Lehtinen M., Koivula T. Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br. J. Cancer 1988, 58:213-215.
19. Kokko R., Holli K., Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur. J. Cancer 2002, 38:1189-1193.
20. Lumachi F., Brandes A.A., Boccagni P., Polistina F., Favia G., D'Amico D.F. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res. 1999, 19:4485-4489.
21. Molina R., Jo J., Filella X., et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999, 19:2551-2555.
22. Nicolini A., Tartarelli G., Carpi A., et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6:269.
23. Pectasides D., Pavlidis N., Gogou L., Antoniou F., Nicolaides C., Tsikalakis D. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am. J. Clin. Oncol. 1996, 19:459-464.
24. Safi F., Kohler I., Rottinger E., Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991, 68:574-582.
25. Stieber P., Molina R., Chan D.W., et al. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin. Lab. 2003, 49:15-24.
26. Vizcarra E., Lluch A., Cibrian R., et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res. Treat. 1996, 37:209-216.
27. al-Jarallah M.A., Behbehani A.E., el-Nass S.A., et al. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur. J. Surg. Oncol. 1993, 19:74-19:79.
28. Lamerz R. CEA determination in the follow-up of extracolorectal neoplasms. Int. J. Biol. Markers 1992, 7:171-178.
29. Soletormos G., Nielsen D., Schioler V., et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann. Oncol. 1993, 4:861-869.
30. Hayes D.F., Zurawski V.R., Kufe D.W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clin. Oncol. 1986, 4:1542-1550.
31. Coveney E.C., Geraghty J.G., Sherry F., et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int. J. Biol. Markers 1995, 10:35-41.
32. Engel K., Schmid H., Hanke J., Kaufmann M., Muller A. CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer. Geburtshilfe Frauenheilkd. 1988, 48:309-312.